Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.


Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first-in-class inhibitor of the nuclear export protein XPO1, in this phase 1 trial to assess safety and determine a recommended phase 2 dose (RP2D). Seventy-nine patients with various NHL… (More)
DOI: 10.1182/blood-2016-11-750174


7 Figures and Tables